Getting To Know The Effective Eczetibibe 'Rosuvastatin' Combination Therapy Lowers Bad Cholesterol Faster

JAKARTA - Now a new therapy for handling dyslipidemia that combines Ezetimibe and Rouvastatin is officially introduced in Indonesia. These two active substances work through two different routes, namely Rouvastatin lowering production of bad cholesterol (LDL) in the liver, while Ezetimibe reduces cholesterol absorption from the fine intestines.

This new dyslipidemia therapy was launched by Daewoong Pharmaceutical Indonesia (DPI). This product is present as an answer to the need for more effective therapy in reducing cholesterol levels, especially LDL-C which is one of the main risk factors for cardiovascular disease.

With this dual approach, the decrease in LDL-C levels is proven to be more optimal even with low doses, when compared to the use of single statins. DPI provides three dose variants, namely 10/5 mg, 10/10 mg, and 10/20 mg, so doctors have a more precise therapeutic option according to the patient's cardiovascular risk profile.

The drug launch took place at a scientific cemetery at the JW Marriott Hotel Jakarta, which was held with the Indonesian Kardiology Association (PERKI) on Saturday, November 29, 2025. More than 200 cardiologists were present, including the Chairman of PERKI dr. Ade Meidian Ambari, SpJP(K), PhD, Prof. Kang Seok Min, MD., Ph.D. from the Korean Society of Cardiology, as well as Prof. Won Ho Youn, MD., Ph.D. from Chung-Ang University Hospital.

With the theme 'Future Respectives on Dual-Pathway Strategies in Cardiovascular Risk Reduction,' this convention discusses scientific evidence as well as the latest trends related to combinational therapy to lower cardiovascular risk.

In his remarks, Baik In Hyun, Head of Indonesia Business Division and Director of DPI emphasized the company's commitment to providing scientific research-based therapy.

"This launch shows our commitment to improve the patient's quality of life through proven therapy, and through close cooperation with medical personnel," he said in his official statement.

He also conveyed the company's plan to expand its innovative therapeutic line.

"In the future, we will add a therapeutic portfolio for diabetes, hypertension, and heart failure, including strengthening research collaboration with PERKI and experts from both countries," he said.

On the same occasion, Baik In Hyun also emphasized that this combination product is one of the important pillars of the company's development in Indonesia.

"The drugs we developed are the largest portfolio for companies and include new chemical entities. We are proud because in the last two years we have succeeded in presenting three new products," he said.

PerKI chairman, dr. Ade Meidian Ambari, SpJP(K), PhD, explained the big challenges that Indonesia still faces in managing LDL-C.

"More than 80 percent ofcut heart disease patients have not yet reached the LDL-C target of 70 mg/dL, and only about 8.5 percent have reached the target for very high risk at 55 mg/dL," he explained.

He assessed that the combination therapy strategy could help improve the achievement of these targets.

"The ESC guidelines emphasize the 'lower and faster, better' principles. This means lowering the LDL-C as early as possible, especially with combinational therapy, which is very important for effective prevention." he said.

From South Korea, Prof. Won Ho Youn, MD., Ph.D., added various scientific evidence related to the effectiveness of combination therapy. In his presentation entitled 'Dual Pathway LDL-C Lowering: Global Environment and Real-World Experience with Ezetimibe + Rouvastatin', he emphasized that strategies that combine simultaneous inhibition of absorption and cholesterol production are increasingly recognized as an important approach to achieving global LDL-C targets.

"This combination of fire helps patients reach the target faster and improve long-term compliance," he said.

He also mentioned ACTE (2011) and RACING (2022) research which shows that combination therapy provides a larger decrease in LDL-C with lower side effects than high-dose statins.

The chairman of the Korean Society of Cardiology, Prof. Kang Seok Min, MD., Ph.D., also explained the development of the use of combination therapy in his country.

He said the combination Ezetimibe prescription rate increased from 4.5 percent in 2016 to 22.5 percent in 2020. On the other hand, the achievement of the LDL-C target in South Korea also increased significantly from 41.4 percent to 62.5 percent.

"For high-risk patients, starting combinatorial therapy from the start without delaying is a better key to clinical outcomes." he said.

With the presence of this new combination drug, including tablet 10/5 mg which is the first in Indonesia, DPI targets the expansion of patient access through stronger cooperation with hospitals and health institutions.

The company is also committed to expanding the reach of innovative therapies through three available dose options, so that more and more patients can benefit from a combination therapy approach.